

CURRICULUM VITAE

AARON E. MILLER, M.D.

CURRENT POSITION

March 2004—Present ---Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY 10029

March 2004—Present---Professor of Neurology, Icahn School of Medicine at Mount Sinai

ACADEMIC APPOINTMENTS

Instructor in Neurology; Albert Einstein College of Medicine, Bronx, NY; 1977-78

Assistant Professor of Neurology; Albert Einstein College of Medicine; Bronx, NY 1978-1981

1981--1999: Visiting Assistant Professor of Neurology, Albert Einstein College of Medicine, Bronx, New York

1985--1992: Associate Professor of Clinical Neurology, State University of New York Health Sciences Center at Brooklyn

1992-2003: Professor of Clinical Neurology, State University of New York Health Sciences Center at Brooklyn

2001–2004: Clinical Professor of Neurology, Mt. Sinai School of Medicine, New York, NY

2004—present: Professor of Neurology, Mt. Sinai School of Medicine, (now Icahn School of Medicine at Mount Sinai) New York, NY

HOSPITAL APPOINTMENTS

Attending Neurologist, Bronx Municipal Hospital Center 1978-1999

Attending Neurologist, Albert Einstein College Hospital 1978-1981

Director, Division of Neurology and Attending Neurologist, Maimonides Medical Center, Brooklyn, New York 1981—present

Attending Neurologist, Kings County Hospital Center, 1981-2001

Attending Neurologist, Metropolitan Jewish Geriatric Center 1981--present

Attending Neurologist, Mt. Sinai Hospital (now Icahn School of Medicine at Mount Sinai), New York, 1999—present

EDUCATION:

B.A., June, 1964, Magna cum laude, with Honors in Psychology
Brandeis University
Waltham, Massachusetts

M.D.,
June, 1968
New York University School of Medicine
New York, New York

POSTDOCTORAL TRAINING:

Internship: July 1, 1968--June 30, 1969
Bronx Municipal Hospital Center
Bronx, New York
Straight Medicine

Junior Assistant Residency July 1, 1969--June 30, 1970
(Medicine): Bronx Municipal Hospital Center
Bronx, New York

Neurology Residency: July 1, 1970--June 30, 1971
July 1, 1973--June 30, 1975
(Chief resident, '74-'75)
Albert Einstein College of Medicine
Bronx, New York

Postdoctoral Fellowship (Neurovirology and immunology):

Department of Epidemiology
Division of Infectious Disease
(Laboratory of Dr. Neal Nathanson)
Johns Hopkins University School of Hygiene and Public Health
Baltimore, MD.
July 1, 1975—June 30, 1977

Department of Microbiology and Immunology
(Laboratory of Dr. Barry Bloom)
Albert Einstein College of Medicine
Bronx, New York
July 1, 1977—June 30, 1978

Recipient of National Multiple Sclerosis Society Fellowship, July 1, 1976--June 30, 1978.

MILITARY SERVICE

Lieutenant Commander

United States Naval Reserve

Active duty obligation fulfilled at St. Albans Naval Hospital, Queens, New York, July, 1971--June, 1973

CERTIFICATION

National Board of Medical Examiners, July 1, 1969

Certification, American Board of Internal Medicine, 1972

Certification in Neurology, American Board of Psychiatry and Neurology, April, 1977.

LICENSURE

Medical License, New York State Dept. of Education, July, 1969—current, #104308

Medical License, Maryland, 1975-77, voluntarily inactive

HONORS/AWARDS/PATENTS

Phi beta kappa, Mu chapter of Massachusetts, Brandeis University, 1964

Alpha omega alpha, New York University School of Medicine, 1968

Teacher-Investigator Award, NINCDS, July, 1979--April, 1981

Fellow, American Academy of Neurology. 1985

Member (elected), American Neurological Association, 1998

OTHER PROFESSIONAL APPOINTMENTS

Councillor, American Society for Neurologic Investigation (1982-1984)

Brooklyn Neurological Society, Vice-president (1986-1988); Secretary/treasurer (1983-1986)

Editorial Board, MS Quarterly (1982--2001)

Editorial Board, MS Indicative Abstracts (1985--1988)

Editorial Board, Multiple Sclerosis Research Reports, Demos Publications (1989--1991)

Co-chairman, Professional Advisory Committee, New York Multiple Sclerosis Society (1988-1991; member from 1983)

National Medical Advisory Committee, National Multiple Sclerosis Society (1988--1991; 1994--present; Chairman 2002--2010)

Council of PAC Chairmen and Clinic Directors, National Multiple Sclerosis Society (1988--1991)

Subcommittee on Foreign Education, American Academy of Neurology (1989--1994)

Chairman, Program Accreditation and Development Subcommittee (formerly known as Regional Education Subcommittee), American Academy of Neurology (1989-1997)

Chairman, Clinical Advisory Committee, New York Multiple Sclerosis Society (1991--2004)

Data and Safety Monitoring Committee, A randomized-double blind placebo-controlled trial of copolymer 1 in relapsing-remitting multiple sclerosis (sponsored by Teva), (1991—1994)

Chairman, Professional Education Committee, National Multiple Sclerosis Society (1993--2002)

President-elect, Consortium of Multiple Sclerosis Centers (1993-- 1994)

Executive Board, Consortium of Multiple Sclerosis Centers (1993--1999)

President, Consortium of Multiple Sclerosis Centers (1994--1995)

Task Force on Clinical Outcomes Assessment, National Multiple Sclerosis Society (1994--1997)

Chairman, Section on Multiple Sclerosis, American Academy of Neurology (1996-1997)

Chairman, End-point committee, A randomized, double-blind placebo-controlled study of Avonex™ (interferon beta 1-a) in the treatment of subjects at high risk for development of multiple sclerosis following the first onset of an isolated demyelinating event. (Biogen, Lawrence Jacobs, PI) (1996-2000)

Member, Annual Meeting Management Committee, American Academy of Neurology (1997—2003)

Chairman, Annual Meeting Subcommittee, American Academy of Neurology (1997-2003)

Co-chairman, Education Committee, American Academy of Neurology (1997-2003)

Member, Research Programs Advisory Committee, National Multiple Sclerosis Society (2003—2020)

Member, Steering Committee, A double-blind, placebo-controlled, parallel group safety study of natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple sclerosis. (Biogen, Inc.) (2003—2005)

Member, Board of Directors, National Multiple Sclerosis Society (2003—2017)

Editor, Continuum. American Academy of Neurology (2003—2012). (Continuum is the bimonthly continuing education journal of the AAN)

Member, American Academy of Neurology/American Board of Psychiatry and Neurology Leadership Committee (2003—present)

Member, Publications Committee, American Academy of Neurology (2003—present)

Member, Steering Committee for development of Teriflunomide as treatment for Multiple Sclerosis; Sanofi-Aventis, 2004—2013

Member, Data Monitoring and Safety Committee for Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects with Multiple Sclerosis, Abbott Laboratories, 2006--2008

Member, Data Monitoring and Safety Committee for Study of SB-683699 Compared to Placebo in Subjects with Relapsing-Remitting Multiple Sclerosis, Glaxo Smith Kline, 2007—2012

Chairman, Data Monitoring and Safety Committee for A Study of Safety and Efficacy of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis, ONO, 2009—2013.

Chairman, Data Monitoring and Safety Committee for A 12 Week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients, Daiichi-Sankyo, 2009—2011

Member, Board of Directors, American Academy of Neurology 2009—2013

Secretary, Board of Directors and member of Executive Committee of the Board, American Academy of Neurology, 2013--2017

Chairman, Editors-in-chief Committee, American Academy of Neurology (2009—2011)

Member, Education Committee, World Federation of Neurology, 2010—2012

Member, Scientific Working Group, advising Canadian Institute of Health Research on Chronic Cerebrospinal Venous Insufficiency, 2010--current

Member, Data Monitoring and Safety Committee for Phase 3 trial of ofatumumab in relapsing multiple sclerosis, Glaxo Smith Kline, 2012—2014

Member, Publications Committee, World Federation of Neurology, 2012—2014

Editor, Continuum Audio, a joint venture of Audio Digest and American Academy of Neurology, 2011—present

Section Editor (Therapy), Multiple Sclerosis and Related Disorders, 2011—present

Participant, Advisory Panel on Costs of Medications for Multiple Sclerosis, National Multiple Sclerosis Society, March 2012

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.